<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33315519</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1554-8635</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Autophagy</Title>
          <ISOAbbreviation>Autophagy</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1).</ArticleTitle>
        <Pagination>
          <StartPage>3221</StartPage>
          <EndPage>3237</EndPage>
          <MedlinePgn>3221-3237</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15548627.2020.1851492</ELocationID>
        <Abstract>
          <AbstractText>Liver dysfunction is an outstanding dose-limiting toxicity of gefitinib, an EGFR (epidermal growth factor receptor)-tyrosine kinase inhibitor (TKI), in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to elucidate the mechanisms underlying gefitinib-induced hepatotoxicity, and provide potentially effective intervention strategy. We discovered that gefitinib could sequentially activate macroautophagy/autophagy and apoptosis in hepatocytes. The inhibition of autophagy alleviated gefitinib-induced apoptosis, whereas the suppression of apoptosis failed to lessen gefitinib-induced autophagy. Moreover, liver-specific <i>Atg7</i><sup>+/-</sup> heterozygous mice showed less severe liver injury than vehicle, suggesting that autophagy is involved in the gefitinib-promoted hepatotoxicity. Mechanistically, gefitinib selectively degrades the important anti-apoptosis factor COX6A1 (cytochrome c oxidase subunit 6A1) in the autophagy-lysosome pathway. The gefitinib-induced COX6A1 reduction impairs mitochondrial respiratory chain complex IV (RCC IV) function, which in turn activates apoptosis, hence causing liver injury. Notably, this autophagy-promoted apoptosis is dependent on PLK1 (polo like kinase 1). Both AAV8-mediated <i>Plk1</i> knockdown and PLK1 inhibitor BI-2536 could mitigate the gefitinib-induced hepatotoxicity <i>in vivo</i> by abrogating the autophagic degradation of the COX6A1 protein. In addition, PLK1 inhibition could not compromise the anti-cancer activity of gefitinib. In conclusion, our findings reveal the gefitinib-hepatotoxicity pathway, wherein autophagy promotes apoptosis through COX6A1 degradation, and highlight pharmacological inhibition of PLK1 as an attractive therapeutic approach toward improving the safety of gefitinib-based cancer therapy.<b>Abbreviations:</b> 3-MA: 3-methyladenine; AAV8: adeno-associated virus serotype 8; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; CCCP: carbonyl cyanide m-chlorophenylhydrazone; CHX: cycloheximide; COX6A1: cytochrome c oxidase subunit 6A1; c-PARP: cleaved poly(ADP-ribose) polymerase; CQ: chloroquine; GOT1/AST: glutamic-oxaloacetic transaminase 1, soluble; GPT/ALT: glutamic pyruvic transaminase, soluble; HBSS: Hanks´ balanced salt solution; H&amp;E: hematoxylin and eosin; MAP1LC3/LC3: microtubule associated proteins 1 light chain 3; PLK1: polo like kinase 1; RCC IV: respiratory chain complex IV; ROS: reactive oxygen species; TUBB8: tubulin beta 8 class VIII.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Peihua</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Jiangxia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xueqin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People´s Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shao</LastName>
            <ForeName>Jinjin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhifei</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Nengming</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Clinical Pharmacology, Affiliated Hangzhou First People´s Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Qiaojun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Autophagy</MedlineTA>
        <NlmUniqueID>101265188</NlmUniqueID>
        <ISSNLinking>1554-8627</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.9.3.1</RegistryNumber>
          <NameOfSubstance UI="C472628">Cox6a1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.9.3.1</RegistryNumber>
          <NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C090134">polo-like kinase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056486" MajorTopicYN="Y">Chemical and Drug Induced Liver Injury</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003576" MajorTopicYN="N">Electron Transport Complex IV</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Autophagy</Keyword>
        <Keyword MajorTopicYN="Y">COX6A1</Keyword>
        <Keyword MajorTopicYN="Y">PLK1</Keyword>
        <Keyword MajorTopicYN="Y">gefitinib</Keyword>
        <Keyword MajorTopicYN="Y">hepatotoxicity</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflicts of interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>17</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33315519</ArticleId>
        <ArticleId IdType="pmc">PMC8526032</ArticleId>
        <ArticleId IdType="doi">10.1080/15548627.2020.1851492</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004. 
Aug
20;305(5687):1163–1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15284455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004. 
May
20;350(21):2129–2139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15118073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen XQ, Pan YL, Zhang SR, et al. Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: a case report and literature review. Oncol Lett. 2014. 
Mar;7(3):878–880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3919904</ArticleId>
            <ArticleId IdType="pubmed">24527096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010. 
Feb;11(2):121–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20022809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah RR, Morganroth J, Shah DR.. 
Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013. 
July;36(7):491–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23620168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kijima T, Shimizu T, Nonen S, et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J clin oncol. 2011. 
July
01;29(19):e588–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21502555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rautou PE, Mansouri A, Lebrec D, et al. Autophagy in liver diseases. J Hepatol. 2010. 
Dec;53(6):1123–1134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20810185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S, Dou X, Ning H, et al. Sirtuin 3 acts as a negative regulator of autophagy dictating hepatocyte susceptibility to lipotoxicity. Hepatology. 2017. 
Sept;66(3):936–952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5570642</ArticleId>
            <ArticleId IdType="pubmed">28437863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K. Autophagy and apoptosis in liver injury. Cell Cycle. 2015;14(11):1631–1642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4614283</ArticleId>
            <ArticleId IdType="pubmed">25927598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med. 2008. 
Sept;14(9):959–965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2722716</ArticleId>
            <ArticleId IdType="pubmed">18690243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodall ML, Fitzwalter BE, Zahedi S, et al. The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell. 2016. 
May
23;37(4):337–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4886731</ArticleId>
            <ArticleId IdType="pubmed">27219062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gump JM, Staskiewicz L, Morgan MJ, et al. Autophagy variation within a cell population determines cell fate through selective degradation of Fap-1. Nat Cell Biol. 2014. 
Jan;16(1):47–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3876036</ArticleId>
            <ArticleId IdType="pubmed">24316673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui X, Chen R, Wang Z, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013. 
Oct
10;4:e838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824660</ArticleId>
            <ArticleId IdType="pubmed">24113172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Y, Zhang Y, Zhang L, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther. 2012. 
Jan;11(1):154–164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3302182</ArticleId>
            <ArticleId IdType="pubmed">22057914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugita S, Ito K, Yamashiro Y, et al. EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. Biochem Biophys Res Commun. 2015. 
May
22;461(1):28–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25858318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz F, Garcia S, Hernandez D, et al. Pathophysiology and fate of hepatocytes in a mouse model of mitochondrial hepatopathies. Gut. 2008. 
Feb;57(2):232–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2730640</ArticleId>
            <ArticleId IdType="pubmed">17951359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamiya G, Makino S, Hayashi M, et al. A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth disease. Am J Hum Genet. 2014. 
Sept
4;95(3):294–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4157141</ArticleId>
            <ArticleId IdType="pubmed">25152455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho C, Davis J, Anderson F, et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J clin oncol. 2005. 
Nov
20;23(33):8531–8533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16293881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005. 
July;54(7):1024–1033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1774601</ArticleId>
            <ArticleId IdType="pubmed">15951554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jing K, Song KS, Shin S, et al. Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy. 2011. 
Nov;7(11):1348–1358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3242799</ArticleId>
            <ArticleId IdType="pubmed">21811093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komatsu M, Waguri S, Ueno T, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005. 
May
9;169(3):425–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2171928</ArticleId>
            <ArticleId IdType="pubmed">15866887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007. 
Dec
14;131(6):1149–1163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18083104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komatsu M, Kurokawa H, Waguri S, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010. 
Mar;12(3):213–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20173742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007. 
Sept;8(9):741–752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17717517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McWilliams TG, Prescott AR, Allen GF, et al. mito-QC illuminates mitophagy and mitochondrial architecture in vivo. J Cell Biol. 2016. 
Aug
1;214(3):333–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4970326</ArticleId>
            <ArticleId IdType="pubmed">27458135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cogliati S, Calvo E, Loureiro M, et al. Mechanism of super-assembly of respiratory complexes III and IV. Nature. 2016. 
Nov
24;539(7630):579–582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27775717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ennis HL, Lubin M. Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells. Science. 1964. 
Dec
11;146(3650):1474–1476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14208575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A. 1982. 
Mar;79(6):1889–1892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC346086</ArticleId>
            <ArticleId IdType="pubmed">6952238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chlumska A, Chlumsky J, Malina L. Liver changes in porphyria cutanea tarda patients treated with chloroquine. Br J Dermatol. 1980. 
Mar;102(3):261–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7370174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fries JF, Singh G, Lenert L, et al. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheumatism. 1990. 
Nov;33(11):1611–1619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2242059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen LL, Wang YB, Song JX, et al. Phosphoproteome-based kinase activity profiling reveals the critical role of MAP2K2 and PLK1 in neuronal autophagy. Autophagy. 2017. 
Sept
21;13:1969–1980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5788482</ArticleId>
            <ArticleId IdType="pubmed">28933595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruf S, Heberle AM, Langelaar-Makkinje M, et al. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy. 2017;13(3):486–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5361591</ArticleId>
            <ArticleId IdType="pubmed">28102733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valianou M, Cox AM, Pichette B, et al. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Cell Cycle. 2015. 
Feb
1;14(3):399–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4353234</ArticleId>
            <ArticleId IdType="pubmed">25565629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benkafadar N, Menardo J, Bourien J, et al. Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med. 2017. 
Jan;9(1):7–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5210089</ArticleId>
            <ArticleId IdType="pubmed">27794029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao M, Hartke C, Jimeno A, et al. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005. 
May
05;819(1):73–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15797523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Chen M, Zhong W, et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 2013. 
Mar;14(2):188–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22846582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nigade PB, Gundu J, Sreedhara Pai K, et al. Prediction of tissue-to-plasma ratios of basic compounds in mice. Eur J Drug Metab Pharmacokinet. 2017. 
Oct;42(5):835–847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28194579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yonesaka K, Suzumura T, Tsukuda H, et al. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity. Anticancer Res. 2014. 
Sept;34(9):5211–5215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25202117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zenke Y, Umemura S, Sugiyama E, et al. Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2016. 
Sept;99:1–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27565905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nezis IP, Shravage BV, Sagona AP, et al. Autophagy as a trigger for cell death: autophagic degradation of inhibitor of apoptosis dBruce controls DNA fragmentation during late oogenesis in Drosophila. Autophagy. 2010. 
Nov;6(8):1214–1215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3973654</ArticleId>
            <ArticleId IdType="pubmed">20935512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolvetang EJ, Johnson KL, Krauer K, et al. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett. 1994. 
Feb
14;339(1–2):40–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8313978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narendra D, Tanaka A, Suen DF, et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008. 
Dec
1;183(5):795–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2592826</ArticleId>
            <ArticleId IdType="pubmed">19029340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan J, Horlin A, Hock B, et al. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol. 1997. 
Apr;150(4):1165–1172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1858156</ArticleId>
            <ArticleId IdType="pubmed">9094972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song B, Davis K, Liu XS, et al. Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer´s disease. Aging-Us. 2011. 
Sept
3;3(9):846–851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3227450</ArticleId>
            <ArticleId IdType="pubmed">21931181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trakala M, Partida D, Salazar-Roa M, et al. Activation of the endomitotic spindle assembly checkpoint and thrombocytopenia in Plk1-deficient mice. Blood. 2015. 
Oct
01;126(14):1707–1714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26185128</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
